ASCO-GU – Keytruda strengthens its kidney cancer monopoly
Merck adds an overall survival benefit while Bristol sinks further.
ASCO-GU – Opdivo's approval might have scuppered Keynote-123
The Bristol drug's availability for adjuvant bladder cancer threw Keynote-123 out of kilter.
ASCO-GI – confirmation for Bristol’s combo, but is there more?
Opdivo plus Yervoy scores a remarkable survival benefit in Checkmate-8HW, whose control arm presents some comparability difficulties.
Another setback for Opdualag's post-melanoma plan
The latest failure, in colorectal cancer, follows a recent disappointment in second-line liver.
November's CHMP meeting sets up a GSK-Novartis battle
Novartis' Jakafi faces competition from GSK's momelotinib, while Astra looks over its shoulder at Merck in biliary tract cancer.
A changing of the guard in stomach cancer?
Akeso’s cadonilimab hits in its first-line study, but there’s no US data and no US partner.
